Autolus Therapeutics (AUTL) Stock Price, News & Analysis

Company Overview

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: $2.00 to $2.07
• 50-Day Range: $1.14 to $2.35
• 52-Week Range: $1.11 to $5.00
• Volume: 2.70 million shs
• Average Volume: 1.57 million shs
• Market Capitalization: $531.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.32
• Consensus Rating: Buy

Autolus Therapeutics Stock Analysis - MarketRank™

Autolus Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 538th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Autolus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Autolus Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Autolus Therapeutics are expected to grow in the coming year, from ($0.94) to ($0.83) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Autolus Therapeutics is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Autolus Therapeutics is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Autolus Therapeutics has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.85% of the float of Autolus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Autolus Therapeutics has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in Autolus Therapeutics has recently increased by 9.25%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Autolus Therapeutics does not currently pay a dividend.

Dividend Growth

Autolus Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.85% of the float of Autolus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Autolus Therapeutics has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in Autolus Therapeutics has recently increased by 9.25%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.41

News Sentiment

Autolus Therapeutics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Autolus Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 11 people have searched for AUTL on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.

MarketBeat Follows

4 people have added Autolus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Autolus Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

25.70% of the stock of Autolus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

72.83% of the stock of Autolus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AUTL Stock Analysis - Frequently Asked Questions

How have AUTL shares performed this year?

Autolus Therapeutics' stock was trading at $2.35 at the beginning of 2025. Since then, AUTL shares have decreased by 13.6% and is now trading at $2.03.
View the best growth stocks for 2025 here.

How were Autolus Therapeutics' earnings last quarter?

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) issued its quarterly earnings data on Thursday, May, 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by $0.02. The firm earned $8.98 million during the quarter, compared to analyst estimates of $1.59 million.
Read the conference call transcript.

When did Autolus Therapeutics IPO?

Autolus Therapeutics (AUTL) raised $125 million in an initial public offering on Friday, June 22nd 2018. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

Who are Autolus Therapeutics' major shareholders?

Autolus Therapeutics' top institutional shareholders include Wellington Management Group LLP (10.18%), Armistice Capital LLC (4.13%), Affinity Asset Advisors LLC (1.14%) and Perpetual Ltd (0.46%).

How do I buy shares of Autolus Therapeutics?

Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Autolus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Autolus Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and CymaBay Therapeutics (CBAY).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 6/18/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AUTL
• CIK: 1730463
• Web: www.autolus.com
• Phone: 442038296230
• Fax: N/A
• Employees: 330
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.32
• High Stock Price Target: $13.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +359.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$220.66 million
• Net Margins: N/A
• Pretax Margin: -2,600.95%
• Return on Equity: -52.82%
• Return on Assets: -29.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.24
• Quick Ratio: 9.02

Sales & Book Value

• Annual Sales: $9.01 million
• Price / Sales: 59.96
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.61 per share
• Price / Book: 1.26

Miscellaneous

• Outstanding Shares: 266,141,000
• Free Float: 197,743,000
• Market Cap: $540.27 million
• Optionable: Optionable
• Beta: 1.75